Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

PURPOSE: Programmed death 1 is an immune checkpoint that suppresses antitumor immunity. Nivolumab, a fully human immunoglobulin G4 programmed death 1 immune checkpoint inhibitor antibody, was active and generally well tolerated in patients with advanced solid tumors treated in a phase I trial with e...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Clin Oncol
Главные авторы: Gettinger, Scott N., Horn, Leora, Gandhi, Leena, Spigel, David R., Antonia, Scott J., Rizvi, Naiyer A., Powderly, John D., Heist, Rebecca S., Carvajal, Richard D., Jackman, David M., Sequist, Lecia V., Smith, David C., Leming, Philip, Carbone, David P., Pinder-Schenck, Mary C., Topalian, Suzanne L., Hodi, F. Stephen, Sosman, Jeffrey A., Sznol, Mario, McDermott, David F., Pardoll, Drew M., Sankar, Vindira, Ahlers, Christoph M., Salvati, Mark, Wigginton, Jon M., Hellmann, Matthew D., Kollia, Georgia D., Gupta, Ashok K., Brahmer, Julie R.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Clinical Oncology 2015
Предметы:
ORIGINAL REPORTS
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4672027/
https://ncbi.nlm.nih.gov/pubmed/25897158
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.58.3708
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы